This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Best Biotech Stocks & ETFs for mRNA, Gene Editing
by Neena Mishra
Here is what you should know about investing in these life changing technologies.
PFEPositive Net Change MRNAPositive Net Change TBIONegative Net Change IBBNegative Net Change EDITNegative Net Change XBINegative Net Change CRSPNegative Net Change CHNAPositive Net Change BNTXNegative Net Change CVACNegative Net Change
biotechs coronavirus
Is a Beat in the Cards for Twist (TWS) This Earnings Season?
by Zacks Equity Research
Investors will focus on the top-line and bottom-line numbers when Twist (TWST) reports fiscal second-quarter 2021 results.
IRWDPositive Net Change KALANegative Net Change TWSTPositive Net Change
biotechs pharmaceuticals
Alkermes' (ALKS) Q1 Earnings Rise Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Alkermes' (ALKS) earnings rise year over year in the first quarter of 2021. Revenues surpass estimates.
ASLNNegative Net Change
biotechs earnings
Bristol-Myers (BMY) Misses on Q1 Earnings, Opdivo Sales Decline
by Zacks Equity Research
Bristol-Myers (BMY) misses earnings and sales estimates in the first quarter on weak Opdivo sales.
PFEPositive Net Change EXELPositive Net Change BMYPositive Net Change
biotechs earnings medical pharmaceuticals
Apellis' (APLS) Q1 Earnings Miss, Pegcetacoplan in Focus
by Zacks Equity Research
Apellis' (APLS) earnings lag estimates in the first quarter of 2021. Main focus of the company is on its lead pipeline candidate, pegcetacoplan.
ALXNPositive Net Change NBRVPositive Net Change APLSNegative Net Change ASLNNegative Net Change
biotechs earnings
Biotech Stock Roundup: BIIB, AMGN's Q1 Earnings Updates & Other Pipeline News
by Zacks Equity Research
The biotech sector was in focus last week with earnings updates form Biogen (BIIB) and Amgen (AMGN), and regulatory updates from Bristol Myers (BMY), among others.
BIIBPositive Net Change GILDNegative Net Change BMYPositive Net Change AMGNPositive Net Change VRTXPositive Net Change CRSPNegative Net Change
biotechs medical pharmaceuticals
Pharma/Biotech Stocks' Q1 Earnings Queued for Apr 29: MRK, BMY & More
by Zacks Equity Research
Let us take a look at what is in store for some of the pharma/biotech stocks, which are scheduled to report on Apr 29.
BIIBPositive Net Change JNJPositive Net Change GILDNegative Net Change MRKNegative Net Change NVSPositive Net Change BMYPositive Net Change VRTXPositive Net Change
biotechs earnings pharmaceuticals
CRISPR Therapeutics (CRSP) Q1 Earnings Miss, Revenues Rise Y/Y
by Zacks Equity Research
CRISPR Therapeutics' (CRSP) earnings and revenues miss estimates in the first quarter of 2021. Focus on pipeline development.
VRTXPositive Net Change NBRVPositive Net Change CRSPNegative Net Change ASLNNegative Net Change
biotechs earnings
Illumina (ILMN) Q1 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Illumina (ILMN) exhibits an impressive performance by its Instruments segment in the first quarter of 2021 despite pandemic-led business disruptions.
OMCLNegative Net Change ILMNPositive Net Change WSTPositive Net Change GMEDNegative Net Change
biotechs earnings medical
Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Novavax's (NVAX) upcoming first-quarter earnings call, investor focus is expected to be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.
SNYNegative Net Change GILDNegative Net Change NVAXPositive Net Change AXSMNegative Net Change
biotechs
Find Strong Stocks During Earnings Season with this First Profit Screener
by Benjamin Rains
Let's use our 'First Profit' screener to help find strong stocks to consider buying...
UPWKNegative Net Change BNTXNegative Net Change CHWYPositive Net Change
biotechs consumer-staples earnings retail tech-stocks
Novartis (NVS) Q1 Earnings & Sales Miss Estimates on COVID-19 Woes
by Zacks Equity Research
Novartis (NVS) reports lower-than-expected first-quarter results, as the pandemic continues to negatively impact sales.
NVSPositive Net Change BMYPositive Net Change BGNEPositive Net Change CVACNegative Net Change
biotechs earnings pharmaceuticals
Editas (EDIT) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Editas' (EDIT) first-quarter earnings call, investor focus is expected to be on the company's progress with the development of its lead pipeline candidate - EDIT-101.
GILDNegative Net Change ABBVPositive Net Change AXSMNegative Net Change EDITNegative Net Change
biotechs
Bull Of The Day: LeMatire Vascular (LMAT)
by Brian Bolan
In a space that is seeing topline contraction, this stock is seeing topline growth, and lots of it!
LMATNegative Net Change
biotechs
Will Jakafi's Performance Fuel Incyte's (INCY) Q1 Earnings?
by Zacks Equity Research
Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports first-quarter 2021 results.
AZNPositive Net Change GILDNegative Net Change INCYPositive Net Change NVSPositive Net Change
biotechs earnings
What's in Store for Vertex (VRTX) This Earnings Season?
by Zacks Equity Research
On Vertex's (VRTX) first-quarter earnings call, investor focus is likely to be on the sales performance of its triple combo CF drug Trikafta and the company's pipeline progress.
GILDNegative Net Change INCYPositive Net Change VRTXPositive Net Change BNTXNegative Net Change
biotechs
What's in Store for Emergent (EBS) This Earnings Season?
by Zacks Equity Research
On Emergent's (EBS) upcoming first-quarter earnings call, investors are likely to focus on the company's update related to re-start of production at its Bayview facility.
JNJPositive Net Change AZNPositive Net Change GILDNegative Net Change EBSPositive Net Change
biotechs
Alexion (ALXN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Alexion (ALXN) is set to provide updates on revenues and earnings when it releases first-quarter 2021 results on May 3.
ALXNPositive Net Change AZNPositive Net Change GILDNegative Net Change AXSMNegative Net Change
biotechs
Will Strong Veklury and HIV Sales Aid Gilead's (GILD) Q1 Earnings?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales when Gilead (GILD) reports first-quarter 2021 results.
AZNPositive Net Change GILDNegative Net Change MRKNegative Net Change INCYPositive Net Change
biotechs earnings
What's in the Cards for Bristol-Myers (BMY) Q1 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports first-quarter 2021 results.
AZNPositive Net Change INCYPositive Net Change BMYPositive Net Change
biotechs earnings pharmaceuticals
Is a Beat in Store for CRISPR (CRSP) This Earnings Season?
by Zacks Equity Research
On CRISPR Therapeutics' (CRSP) first-quarter earnings call, investor focus will be on updates of the company's progress with the development of its lead gene-editing candidate, CTX001.
GILDNegative Net Change VRTXPositive Net Change AXSMNegative Net Change CRSPNegative Net Change
biotechs
Amgen (AMGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Whether Amgen's (AMGN) sales recovery from the COVID-19 effect continued in the first quarter is what remains to be seen when the company reports.
AZNPositive Net Change RHHBYPositive Net Change GILDNegative Net Change AMGNPositive Net Change
biotechs
Alzheimer's Disease: 5 Stocks on Biotech Radars
by Kevin Cook
While Biogen rides a big-cap rollercoaster, a few small players are creating better trading opps.
BIIBPositive Net Change JAZZPositive Net Change AXSMNegative Net Change AVXLPositive Net Change SAVANegative Net Change
biotechs pharmaceuticals
Ocugen (OCGN) Up on Positive Data for COVID-19 Vaccine Candidate
by Zacks Equity Research
Ocugen (OCGN) gains as partner Bharat Biotech shared positive results of the second interim analysis of its phase III study of COVAXIN.
JNJPositive Net Change PFEPositive Net Change MRNAPositive Net Change OCGNPositive Net Change
biotechs pharmaceuticals
Allogene (ALLO) CAR T Therapy for Myeloma Gets FDA RMAT Tag
by Zacks Equity Research
FDA grants RMAT designation to Allogene's (ALLO) CAR T cell product candidate for multiple myeloma, ALLO-715. The designation will help accelerate development and review of the candidate.
CDMOPositive Net Change ALLONegative Net Change IMNMPositive Net Change
biotechs